Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Lower Respiratory Tract Infection Clinical Trial

Official title:
A Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of ALX 0171 Versus Placebo, in Addition to Standard of Care, in Adults Who Have Undergone Hematopoietic Stem Cell Transplantation and Present With a Respiratory Syncytial Virus Respiratory Tract Infection

Status Withdrawn

Clinical Trial Summary

The primary objective of the study is to evaluate the antiviral effect and safety of inhaled ALX-0171 in adults diagnosed with respiratory syncytial virus (RSV) respiratory tract infection after hematopoietic stem cell transplantation (HSCT).

The secondary objective is to assess the clinical activity, pharmacokinetics (PK), virology, and immunogenicity of inhaled ALX 0171 in adults diagnosed with RSV respiratory tract infection after HSCT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Communicable Diseases
Infection
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Respiratory Tract Infections

Clinical Trial Details

NCT number	NCT03468829
Study type	Interventional
Source	Ablynx
Contact
Status	Withdrawn
Phase	Phase 2
Start date	February 2019
Completion date	May 2020

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT03418571` - Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection	Phase 2
	Completed	`NCT02979431` - Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection	Phase 2